Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026
Company Drug

Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43

Fineline Cube Jun 11, 2025

China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a global,...

Company Deals Medical Device

Tawada Healthcare Secures Series A+ Funding Led by Highlight Capital

Fineline Cube Jun 11, 2025

Indonesian integrated medical equipment service provider Tawada Healthcare (THC) has reportedly raised “tens of millions”...

Company Drug

Merck’s Pimicotinib NDA Accepted for Review by China’s CDE

Fineline Cube Jun 11, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for...

Company Drug

CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval

Fineline Cube Jun 11, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...

Policy / Regulatory

State Council Issues Opinions to Advance Shenzhen’s Healthcare Reforms

Fineline Cube Jun 11, 2025

The General Office of the State Council released the “Opinions on Further Advancing Shenzhen’s Comprehensive...

Company Drug

Eisai’s Urece Arrives in Shanghai, Poised for Chinese Market Entry

Fineline Cube Jun 11, 2025

Eisai’s (TYO: 4523) China unit announced that the first batch of its innovative drug Urece...

Company Drug

Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability

Fineline Cube Jun 11, 2025

France-based Sanofi (NASDAQ: SNY) announced plans to commence shipments of Beyfortus (nirsevimab) in early Q3...

Company Drug

Boai NKY’s LYC001 Receives Clinical Approval in China for Advanced Solid Tumors

Fineline Cube Jun 11, 2025

China-based Boai NKY Medical Holdings Ltd (SHE: 300109) announced that its joint venture company, Beijing...

Company Drug

Sino Biopharmaceutical’s TQB2868 Approved for Phase III Trial in Metastatic Pancreatic Cancer

Fineline Cube Jun 11, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the Center...

Company Drug

Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial

Fineline Cube Jun 11, 2025

Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...

Company Deals

Jiangxi Rimag Plans Acquisition of Changsha Zhongya Medical for RMB 29.5 Million

Fineline Cube Jun 10, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in...

Company Drug

Biogen Launches Qalsody in China for SOD1-ALS Treatment

Fineline Cube Jun 10, 2025

US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...

Company Deals

Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH

Fineline Cube Jun 10, 2025

Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...

Others

China Expands Medical Insurance Coverage in New State Council Guidelines

Fineline Cube Jun 10, 2025

The General Office of the State Council released the “Guidelines on Further Safeguarding and Improving...

Company

WuXi Biologics Commences Construction on Microbial Production Base in Chengdu

Fineline Cube Jun 10, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced the official...

Company Drug

Sihuan Pharma’s Xuanyuening Granted New Indication Review in China

Fineline Cube Jun 10, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases

Fineline Cube Jun 10, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...

Company Deals

Deep Surgery Secures Pre-Series A Funding for Microsurgery Robot Expansion

Fineline Cube Jun 10, 2025

Guangzhou-based microsurgery robot developer Deep Surgery has secured “tens of millions” of renminbi in a...

Company

ImmuneOnco Appoints Zhuli Wu as Chief Medical Officer to Lead Clinical Strategy

Fineline Cube Jun 10, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced the appointment of Zhuli Wu as...

Company Drug

Hengrui Pharmaceuticals Launches Aiweida for HER2-Mutated NSCLC in China

Fineline Cube Jun 10, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its...

Posts pagination

1 … 194 195 196 … 714

Recent updates

  • WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
  • Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
  • Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Company Deals

Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.